Market Overview

Endo Health Solutions to Buy Boca Pharmacal for $225M

Related ENDP
Mylan to Settle with Endo on Frova - Analyst Blog
Mylan Says Judge Has Enforced Settlement Deal Between Mylan, Endo Related to Generic FROVA

Endo Health Solutions (NASDAQ: ENDP) today announced that its Qualitest subsidiary has reached a definitive agreement to acquire privately held Boca Pharmacal, a specialty generics company, for $225 million in cash.  The transaction is expected to enhance the growth platform and pipeline for Endo's Qualitest business and is consistent with Endo's strategic transformation into a leading specialty healthcare company.

Posted-In: News M&A

 

Most Popular

Related Articles (ENDP)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free